Petros Pharmaceuticals (NASDAQ:PTPI) Trading Down 2.1%

Petros Pharmaceuticals, Inc. (NASDAQ:PTPI)’s share price fell 2.1% on Wednesday . The company traded as low as $0.64 and last traded at $0.69. 457,077 shares traded hands during trading, a decline of 55% from the average session volume of 1,006,999 shares. The stock had previously closed at $0.71.

Petros Pharmaceuticals Trading Down 2.1 %

The business’s 50-day moving average is $1.36 and its two-hundred day moving average is $1.37. The company has a current ratio of 1.89, a quick ratio of 1.74 and a debt-to-equity ratio of 0.57. The stock has a market capitalization of $4.74 million, a PE ratio of -0.11 and a beta of 1.91.

Petros Pharmaceuticals (NASDAQ:PTPI) last posted its quarterly earnings data on Monday, April 1st. The company reported ($2.17) earnings per share for the quarter. The firm had revenue of ($0.36) million during the quarter. Petros Pharmaceuticals had a negative net margin of 181.87% and a negative return on equity of 68.90%.

Hedge Funds Weigh In On Petros Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PTPI. Renaissance Technologies LLC acquired a new stake in shares of Petros Pharmaceuticals in the 2nd quarter valued at about $34,000. Schonfeld Strategic Advisors LLC acquired a new stake in shares of Petros Pharmaceuticals in the 2nd quarter valued at about $47,000. Virtu Financial LLC acquired a new stake in shares of Petros Pharmaceuticals in the 4th quarter valued at about $35,000. BlackRock Inc. raised its stake in shares of Petros Pharmaceuticals by 880.2% in the 1st quarter. BlackRock Inc. now owns 191,715 shares of the company’s stock valued at $300,000 after purchasing an additional 172,156 shares in the last quarter. Finally, Vanguard Group Inc. raised its stake in shares of Petros Pharmaceuticals by 114.8% in the 3rd quarter. Vanguard Group Inc. now owns 255,914 shares of the company’s stock valued at $131,000 after purchasing an additional 136,773 shares in the last quarter. 12.34% of the stock is owned by hedge funds and other institutional investors.

Petros Pharmaceuticals Company Profile

Petros Pharmaceuticals, Inc, a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED).